Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01070836 · ClinicalTrials.gov registry record
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
A clinical trial of Relapsing Multiple Sclerosis, sponsored by Biogen.
- Completed
- Registry status
- 35,895
- Enrollment target
- 20
- Study locations
NCT01070836: Completed study of Relapsing Multiple Sclerosis, sponsored by Biogen.
NCT01070836 is a study of Relapsing Multiple Sclerosis that has completed, run by Biogen. The registered enrollment target is 35,895 participants, above the 609-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (5794% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01070836, a study of Relapsing Multiple Sclerosis, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 35,895 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate that the incidence of progressive multifocal Leukoencephalopathy (PML) in natalizumab-treated participants who do not have detectable antibodies to John Cunningham virus (JCV) (antibody negative) is lower than in participants who have detectable antibodies to JCV (antibody positive). The secondary objectives of this study are to: Estimate the incidence of PML in natalizumab-treated participants who are anti-JCV antibody negative and anti-JCV antibody positive, based on a meta-analysis of data obtained from this study and other data sources; Define the prevalence of anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving natalizumab within the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program; Determine changes in anti-JCV antibody status over time.
Conditions Studied
Interventions
- DRUG natalizumab
Study Locations (20)
Arizona
- Research Site - Flagstaff
- Research Site - Gilbert
- Research Site - Phoenix
- Research Site - Phoenix
- Research Site - Phoenix
- Research Site - Phoenix
- Research Site - Scottsdale
- Research Site - Tucson
- Research Site - Tucson
Alabama
- Research Site - Birmingham
- Research Site - Birmingham
- Research Site - Cullman
- Research Site - Tucaloosa
Arkansas
- Research Site - Fayetteville
- Research Site - Little Rock
- Research Site - Sherwood
California
- Research Site - Auburn
- Research Site - Berkeley
- Research Site - Carmel
Alaska
- Research Site - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,895 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-11 |
What the finished NCT01070836 record still lists
NCT01070836 is an observational study that tracks outcomes without assigning an intervention. Its 35,895 participants enrollment target places it among the larger protocols in the corpus, above the 609-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (5794% higher).
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which natalizumab is the first listed.
NCT01070836 names 20 study sites across 5 states, led by Arizona, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01070836 about?
NCT01070836 is a clinical study titled "JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab". The primary objective of this study is to demonstrate that the incidence of progressive multifocal Leukoencephalopathy (PML) in natalizumab-treated participants who do not have detectable antibodies to John Cunningham virus (JCV) (antibody negative) is lower than in participants who have detectable ...
What is the current status of trial NCT01070836?
This trial is currently completed. The enrollment target is 35,895 participants. The study started on 2010-03. Estimated completion is 2015-11.
What conditions does trial NCT01070836 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT01070836?
The interventions under investigation include: natalizumab (DRUG).
Who is sponsoring clinical trial NCT01070836?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01070836 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01070836's enrollment target sits among peer trials
35,895 1st of 23 higher than 23 of 23 other Relapsing Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
RECRUITING
-
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
RECRUITING · Phase 4
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RECRUITING
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
- NCT05796505 · 37,122 participants · NA
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia